This is in line with the knowledge that SK activity promotes B-ALL59, and indicates that SK small-molecule inhibitors may be particularly useful against IL-7R-dependent B-ALL cases. This evidence concerns the gene IL7R and precursor B-cell acute lymphoblastic leukemia.